Agios Pharmaceuticals Stock News

Agios Pharmaceuticals (NASDAQ:AGIO) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$1.57 (-11.3% Y/Y) and…

Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.

Agios Pharmaceuticals' pyrukynd (mitapivat) was approved by the FDA on February 17. Its platform could make AGIO much more valuable by the end of this decade.

Agios Pharmaceuticals With FDA Approval Is A Buy

Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 0 1 0 0

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug Administration approved Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) mitapivat for treating pyruvate kinase deficiency, a rare, inherited metabolic disorder. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) stock tumbled close to 60% after an FDA panel found that data included in the company''s new drug application for pain drug tramadol was inadequate to support approval. GlaxoSmithKline plc (NYSE: GSK ) and Sanofi (NASDAQ: SNY )- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) suffered setbacks after their respective late-stage studies of respiratory syncytial vaccine candidate in pregnant women and Dupixent as a treatment option for skin rash had to be halted. Here are the key catalysts for the unfolding week: Conferences 49th Annual Scientific and Technology Meeting of the American Auditory Society, AAS (hybrid event) Feb. 24-27, in Scottsdale, Arizona & online Multidisciplinary Head and Neck Cancers Symposium (virtual event): Feb. 24-27, in Phoenix, Arizona & online International Society of Nephrology''s World Congress of Nephrology, or WCN, 2022 (hybrid event): Feb. 24-27, in Kuala Lumpur & online PDUFA Dates The FDA has set a PDUFA date of Friday, Feb. 25, for its new drug application for Reata Pharmaceuticals, Inc.''s (NASDAQ: RETA ) Bardoxolone.

Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.

Agios Pharmaceuticals (AGIO) is trading ~2% higher in the pre-market on Friday as Wall Street reacts to the FDA approval for the company’s oral PK activator Pyrukynd (mitapivat) to…

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO) said the U.S. Food and Drug

The U.S. Food and Drug Administration ((FDA)) approved Agios Pharmaceuticals'' (AGIO) Pyrukynd (mitapivat) to treat hemolytic anemia in adults with pyruvate kinase ((PK))…

The FDA approved Agios Pharmaceuticals Inc''s (NASDAQ: AGIO ) Pyrukynd (mitapivat) for hemolytic anemia in adults with pyruvate kinase (PK) deficiency. Pyruvate kinase deficiency is an inherited metabolic disorder of the enzyme pyruvate kinase that affects red blood cells'' survival. The company notes that Pyrukynd is a first-in-class, oral PK activator and the first approved disease-modifying … Full story available on Benzinga.com

The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for hemolytic anemia in adults with pyruvate kinase (PK) deficiency. Pyruvate kinase deficiency is an inherited meta

– Approval Based on Results from ACTIVATE and ACTIVATE-T Phase 3 Studies, Supports Treatment of Adults with PK Deficiency Regardless of Transfusion Status –